However, tumours with high PAK1 levels were more sensitive to the combination treatment than tumours with low PAK1 levels, as evidenced by the reduction in final tumour volume (86% versus 72%) and the calculated CDI values (Fig. 8B and C). This evidence concerns the gene PAK1 and neoplasm.